INNATUS
DEAD

Serial Number

90047593

Owner

Incysus Therapeutics, Inc.

Attorney

Mark Jansen

Filing Date

Jul 10, 2020

Add to watchlist:

No watchlists yet
View on USPTO

INNATUS Trademark

Serial Number: 90047593

INNATUS is a trademark filed by Incysus Therapeutics, Inc. on July 10, 2020. The trademark is classified under Class 5 (Pharmaceuticals), Class 42 (Computer & Scientific). The application is currently no longer active.

Owner Contact Info

Incysus Therapeutics, Inc. (4 trademarks)

79 Madison Avenue
New York, NY 10016

Entity Type: 03

Trademark Details

Filing Date

July 10, 2020

Registration Date

Not Registered

Goods & Services

Pharmaceutical preparations, namely, oncological preparations; Reagents, diagnostics and therapeutic preparations for medical use in oncology; Targeted medical preparations for use in oncology; Pharmaceutical preparations for use in the treatment of cancer and tumors; Pharmaceutical and medicinal preparations for the treatment of cancer and oncological conditions; Pharmaceutical and biological preparations for use in immunotherapies to improve immune system function; Pharmaceutical and biological preparations combining immunotherapies and chemotherapies for treatments in the field of oncology; Medical and veterinary preparations for the delivery of compounds to the body for the treatment and prevention of immunological and oncological diseases and disorders; Pharmaceutical and biological preparations comprised of modified T cells used for multiple modes of treatment against tumor resistance and immunosuppression

Research, development, and evaluation of new products; Pharmaceutical, medicine, and vaccine research and development services; Technical research in the field of pharmaceutical studies; Laboratory analysis and research into new drugs and pharmaceutical products; Development of measuring and testing methods in the field of medicine; Design, development, research, and testing of drugs and pharmaceuticals for the treatment and/or prevention of cancer; Research and development services in the fields of oncology, immunotherapy, chemotherapy and combination therapies for the treatment of cancer and tumors; Providing medical research information in the fields of oncology, immunotherapy, chemotherapy and combination therapies; Scientific advisory services, namely, providing scientific information, advice and consultancy in the field of oncology

Filing History

ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
May 7, 2021 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
May 7, 2021 ABN2
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRN
NON-FINAL ACTION E-MAILED
Oct 20, 2020 GNRT
NON-FINAL ACTION WRITTEN
Oct 20, 2020 CNRT
ASSIGNED TO EXAMINER
Oct 20, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Aug 7, 2020 NWOS
NEW APPLICATION ENTERED
Jul 14, 2020 NWAP